Why the interval between first and second Covishield doses must now be shortened, Top Health News | Latest Health & Healthcare Industry Information and Updates: ET HealthWorld : ETHealthworld.com

How did the dosing interval get longer?Two studies were cited mainly for increasing the interval. In a Lancet study published earlier this year, efficacy result in phase-3 clinical trial of two doses of Oxford-AstraZeneca (Covishield equivalent) was 55., How did the dosing interval get longer?Two studies were cited mainly for increasing the interval. In a Lancet study published earlier this year, efficacy result in phase-3 clinical trial of two doses of Oxford-AstraZeneca (Covishield equivalent) was 55., , Read More